NRX Pharmaceuticals (NRXP) Current Leases (2025 - 2026)

NRX Pharmaceuticals' (NRXP) quarterly Current Leases came in at $108000.0 in Q1 2026, down 48.82% on a QoQ basis from $211000.0 in Q4 2025.

NRX Pharmaceuticals (NRXP) Current Leases (2025 - 2026) Analysis & Trends

NRX Pharmaceuticals (NRXP) has 2 years of Current Leases data on file, last reported at $108000.0 in Q1 2026.

On a quarterly basis, Current Leases changed N/A year-over-year to $108000.0 in Q1 2026; TTM through Mar 2026 was $108000.0, a N/A change from a year earlier, with the FY2025 full-year figure at $211000.0, changed N/A from the prior year.
Current Leases for Q1 2026 stood at $108000.0, down from $211000.0 in the prior quarter.
Over the last five years, Current Leases for NRXP reached as high as $211000.0 in Q4 2025 and fell as low as $87000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Leases (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	531,233.95
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	20.58 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	872,589.03
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	720.00 Mn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	11.00 Mn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	16.61 Mn
10	NRX Pharmaceuticals	137.57 Mn	130.87 Mn	437,000.00	108,000.00

Download Data